Literature DB >> 32296278

Third-generation cephalosporin-resistant urinary tract infections in children presenting to the paediatric emergency department.

Kristopher T Kang1, Karen Ng2, Jennifer Kendrick2, Peter Tilley3, Joseph Ting1, Shahrad Rassekh1, Srinivas Murthy1, Ashley Roberts1.   

Abstract

BACKGROUND: The incidence of antibiotic-resistant urinary tract infections (UTIs) in children is increasing. The purpose of this study was to describe the incidence, clinical characteristics, and risk factors for third-generation cephalosporin-resistant UTIs presenting to the paediatric emergency department (ED).
METHODS: This was a retrospective cohort study conducted at British Columbia Children's Hospital. Children aged 0 to 18 years old presenting to the ED between July 1, 2013 and June 30, 2014 and were found to have UTI due to Enterobacteriaceae and Pseudomonas species were included. Patient demographics, clinical features, laboratory findings, and outcomes were compared using standard statistical analyses. Risk factors for resistant UTIs were analyzed using multiple logistic regression analysis.
RESULTS: There were 294 eligible patients. The median age was 27.4 months. A third-generation cephalosporin-resistant organism was identified in 36 patients (12%). Patients with resistant UTI had lower rates of appropriate empiric antibiotic therapy (25% versus 95.3%, P<0.05), higher rates of hospitalization (38.9% versus 21.3%, P<0.05), higher rates of undergoing a voiding cystourethrogram (19.4% versus 5.0%, P<0.05), and higher rates of UTI recurrence within 30 days (13.9% versus 4.7%, P<0.05). In multivariate analysis, recent hospitalization (odds ratio [OR] 4.3, confidence interval [CI] 1.2 to 16) and antibiotic therapy (OR 3.5, CI 1.5 to 8.5) within the previous 30 days were risk factors for resistant UTI.
CONCLUSIONS: Third-generation cephalosporin-resistant organisms account for a significant proportion of community-acquired paediatric UTIs. Recent hospitalization and antibiotic use are associated with increased risk of resistant UTI.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Canadian Paediatric Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Antibiotic resistance; Antimicrobial stewardship; Urinary tract infections

Year:  2019        PMID: 32296278      PMCID: PMC7147700          DOI: 10.1093/pch/pxy175

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  26 in total

1.  Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients.

Authors:  R Colodner; W Rock; B Chazan; N Keller; N Guy; W Sakran; R Raz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-02-19       Impact factor: 3.267

2.  Incidence, admission rates, and economic burden of pediatric emergency department visits for urinary tract infection: data from the nationwide emergency department sample, 2006 to 2011.

Authors:  Akshay Sood; Frank J Penna; Sriram Eleswarapu; Dan Pucheril; John Weaver; Abd-El-Rahman Abd-El-Barr; Jordan C Wagner; Yegappan Lakshmanan; Mani Menon; Quoc-Dien Trinh; Jesse D Sammon; Jack S Elder
Journal:  J Pediatr Urol       Date:  2015-02-07       Impact factor: 1.830

3.  Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children.

Authors:  Nai-Chia Fan; Hsin-Hang Chen; Chyi-Liang Chen; Liang-Shiou Ou; Tzou-Yien Lin; Ming-Han Tsai; Cheng-Hsun Chiu
Journal:  J Microbiol Immunol Infect       Date:  2013-07-06       Impact factor: 4.399

4.  Treatment of pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in children.

Authors:  Tomohiro Katsuta; Kensuke Shoji; Yasushi Watanabe; Akihiko Saitoh
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129

5.  Changing prevalence of Escherichia coli with CTX-M-type extended-spectrum beta-lactamases in outpatient urinary E. coli between 2003 and 2008.

Authors:  Chao Qi; Varun Pilla; Jessica H Yu; Kurt Reed
Journal:  Diagn Microbiol Infect Dis       Date:  2010-03-12       Impact factor: 2.803

6.  Urine testing and urinary tract infections in febrile infants seen in office settings: the Pediatric Research in Office Settings' Febrile Infant Study.

Authors:  Thomas B Newman; Jane A Bernzweig; John I Takayama; Stacia A Finch; Richard C Wasserman; Robert H Pantell
Journal:  Arch Pediatr Adolesc Med       Date:  2002-01

7.  Urinary tract infections owing to ESBL-producing bacteria: microorganisms change--clinical pattern does not.

Authors:  Zeynep Birsin Özçakar; Fatoş Yalçınkaya; Aslı Kavaz; Gülsüm Kadıoğlu; Atilla H Elhan; Derya Aysev; Haluk Güriz; Mesiha Ekim
Journal:  Acta Paediatr       Date:  2011-03-30       Impact factor: 2.299

8.  Antibiotic resistance patterns of community-acquired urinary tract infections in children with vesicoureteral reflux receiving prophylactic antibiotic therapy.

Authors:  Chi-Hui Cheng; Ming-Horng Tsai; Yhu-Chering Huang; Lin-Hui Su; Yong-Kwei Tsau; Chi-Jen Lin; Cheng-Hsun Chiu; Tzou-Yien Lin
Journal:  Pediatrics       Date:  2008-12       Impact factor: 7.124

9.  Extended-spectrum β-lactamase-producing bacteria causing community-acquired urinary tract infections in children.

Authors:  Orli Megged
Journal:  Pediatr Nephrol       Date:  2014-04-05       Impact factor: 3.714

10.  Clonal dissemination of highly virulent extended-spectrum beta-lactamase-producing Escherichia coli strains isolated from the urine of non-hospitalised patients in Zagreb region.

Authors:  Jasmina Vranes; Tatjana Marijan; Branka Bedenic; Ana Mlinaric-Dzepina; Stjepan Katic; Smilja Kalenic
Journal:  Int J Antimicrob Agents       Date:  2007-10-23       Impact factor: 5.283

View more
  1 in total

1.  Impact of Third-Generation Cephalosporin Resistance on Recurrence in Children with Febrile Urinary Tract Infections.

Authors:  Sin Young Kim; Min Sik Jang; Jihye Kim
Journal:  J Pers Med       Date:  2022-05-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.